|
Jul 29
|
Unveiling Teva Pharmaceutical Industries (TEVA) Q2 Outlook: Wall Street Estimates for Key Metrics
|
|
Jul 25
|
Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease
|
|
Jun 24
|
Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States
|
|
Jun 24
|
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
|
|
Jun 22
|
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a Positive Rating from Analysts?
|
|
May 21
|
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
|
|
May 17
|
Insider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...
|
|
Apr 6
|
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
|
|
Apr 4
|
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
|
|
Apr 3
|
3 No-Brainer Stocks to Buy With $600 Right Now
|
|
Apr 3
|
Biden and Senator Sanders to highlight efforts lower cost of asthma inhalers
|
|
Apr 1
|
UPDATE 1-Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|
|
Apr 1
|
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
|
|
Apr 1
|
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
|
|
Jan 12
|
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
|
|
Jan 10
|
3 No-Brainer Stocks to Buy With $20 Right Now
|
|
Dec 29
|
Corcept loses patent spat against Teva, shares tumble
|
|
Dec 29
|
UPDATE 2-Corcept loses patent spat against Teva, shares tumble
|
|
Dec 28
|
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 26
|
HSBC Sees Opportunity in These 2 Biopharma Giants Ahead of the 2024 Elections
|